Healthcare / BiotechnologyShenzhenCN
$4.64
+0.05 (+1.09%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-227.6M · quality 62.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.2%
↓Gross Margin
39.6%
↓Debt/Equity
0.88
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.2%
FCF CAGR
—
FCF margin
-35.4%
FCF / Net income
3.18x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $824.6M · net income $-91.9M · FCF $-292.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $824.6M | $824.6M | $851.7M | $1.05B | $795.9M |
| Net Income | $-91.9M | $-91.9M | $9.2M | $-24.9M | $-78.4M |
| EBITDA | $-38.5M | $-38.5M | $152.6M | $174.3M | $17.8M |
| EPS | -0.11 | -0.11 | 0.01 | -0.03 | -0.10 |
| Gross Margin | 39.6% | 39.6% | 49.1% | 43.5% | 32.0% |
| Operating Margin | 0.8% | 0.8% | 8.5% | 6.6% | -11.4% |
| Net Margin | -11.1% | -11.1% | 1.1% | -2.4% | -9.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.88 | 0.88 | 0.76 | 0.59 | 0.57 |
| Current Ratio | 0.94 | 0.94 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-292.1M | $-292.1M | $-227.6M | $-60.5M | $-120.7M |
| Returns | |||||
| ROE | -7.2% | -7.2% | 0.7% | -1.8% | -5.6% |
| Valuation | |||||
| P/E | — | — | 476.99 | — | — |
| EV/EBITDA | — | — | 35.30 | 32.79 | 316.84 |
| P/B | 2.95 | 2.95 | 3.20 | 3.66 | 3.57 |
| Growth & Yield | |||||
| Revenue Growth | -3.2% | -3.2% | -18.5% | 31.3% | — |
| EPS Growth | -1095.6% | -1095.6% | 137.0% | 68.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.1%
Start / end P/E
n/dx → n/dx
EPS bridge
0.01 → -0.11
Residual
-21.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.